AARD vs LCTX
AARD: Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing its lead small molecule candidate, ARD-101, for metabolic and rare disease indications. LCTX: Lineage Cell Therapeutics develops allogeneic cell therapy treatments for serious human diseases through its AlloSCOPE™ manufacturing platform and partnerships with major pharmaceutical companies.
Side-by-side fundamentals
| Metric | AARD | LCTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $6.48 | $1.11 | |
| Market cap as of 2026-07-23 | $128M | $278M | |
| PEG as of 2026-07-23 | -1.17 | -0.02 | AARD lower |
| Net margin as of 2026-07-23 | n/a | -431.2% | |
| Gross margin as of 2026-07-23 | n/a | +94.1% | |
| Operating margin as of 2026-07-23 | n/a | -256.5% | |
| ROE as of 2026-07-23 | -61.7% | -151.3% | AARD higher |
| ROA as of 2026-07-23 | -56.3% | -63.3% | AARD higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | AARD lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | -37.1% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -0.3% | |
| Beta as of 2026-07-23 | 4.01 | 1.51 | |
| 1-year return as of 2026-07-22 close | -49.3% | +16.8% | LCTX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.